We are live on
!
Find out more
AC
Ayrton Capital Portfolio holdings
AUM
$14.7M
1-Year Est. Return
12.82%
This Fund
S&P 500
This Quarter
Est. Return
-4.84%
1 Year Est. Return
-12.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$57M
AUM Growth
-$4.55M
(-7.4%)
Cap. Flow
-$5.82M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
51.56%
Holding
131
New
10
Increased
1
Reduced
4
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PharmaCyte Biotech
PMCB
|
+$2.23M |
| 2 |
PAVmed
PAVM
|
+$2.01M |
| 3 |
SLAI
SOLAI Ltd ADS
SLAI
|
+$191K |
| 4 |
AYTU BioPharma
AYTU
|
+$172K |
| 5 |
Innovative Eyewear Inc Series A Warrants 8/16/27
LUCYW
|
+$98.9K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MMV
MultiMetaVerse Holdings Limited Class A Ordinary Share
MMV
|
+$1.78M |
| 2 |
RICO
Agrico Acquisition Corp
RICO
|
+$668K |
| 3 |
WARR
Warrior Technologies Acquisition Company
WARR
|
+$654K |
| 4 |
GGGV
G3 VRM Acquisition Corp. Class A Common Stock
GGGV
|
+$347K |
| 5 |
Mobix Labs
MOBX
|
+$126K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 49.52% |
| 2 | Healthcare | 19.11% |
| 3 | Technology | 6.46% |
| 4 | Consumer Discretionary | 4.18% |
| 5 | Communication Services | 3.17% |
Similar funds
VVA
AR
TAM
RCGI
AEM
CAM
HMP9
LM
Ayrton Capital's Q3 2022 Portfolio in Review
As of Q3 2022, Ayrton Capital held 131 positions worth $57M, down 7.4% from $61.6M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Ayrton Capital withdrew a net $5.82M in Q3 2022, closing 12 positions and reducing 4 holdings. Its most notable exit was MultiMetaVerse Holdings Limited Class A Ordinary Share, an estimated $1.78M position sold in full.
By sector, the portfolio is most concentrated in Financials at 50% of assets, down from 54% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Ayrton Capital opened a new position in PAVmed worth $1.38M.
- Ayrton Capital's largest Q3 2022 buy was PAVmed: 3,555 shares worth $1.38M.
- Ayrton Capital added most to PharmaCyte Biotech in Q3 2022, an estimated $2.23M increase.
- Ayrton Capital's biggest Q3 2022 reduction was Mobix Labs, cutting an estimated $126K.
- Ayrton Capital fully exited MultiMetaVerse Holdings Limited Class A Ordinary Share in Q3 2022, selling an estimated $1.78M.
- Ayrton Capital's ten largest holdings make up 52% of its $57M portfolio in Q3 2022.
- Ayrton Capital opened 10 new positions and closed 12 in Q3 2022.
- Ayrton Capital's portfolio value fell 7.4% quarter-over-quarter to $57M.
Based on Ayrton Capital's 13F filing for Q3 2022, filed 9 Nov 2022.